EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
11. November 2024 03:00 ET
|
EnteroBiotix
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy...